COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
about
Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.Do early premalignant changes in normal breast epithelial cells predict cancer development?p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2Does the act of surgery provoke activation of "latent" metastases in early breast cancer?Potential use of COX-2-aromatase inhibitor combinations in breast cancerCOX inhibitors and breast cancerInflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancerSurgery triggers outgrowth of latent distant disease in breast cancer: an inconvenient truth?Cyclooxygenase-2 and the inflammogenesis of breast cancer.COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situThe Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer.COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatmentA randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells.Oleocanthal, a phenolic derived from virgin olive oil: a review of the beneficial effects on inflammatory diseaseFrom COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.Urinary prostaglandin E2 metabolite and breast cancer risk.Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancerNon-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.Role of traditional and new biomarkers in breast carcinogenesis.Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized.The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumorsProgression of Ductal Carcinoma in Situ from the Pathological Perspective.Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatmentPharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinaseCyclooxygenase-2 enzyme induces the expression of the α-2,3-sialyltransferase-3 (ST3Gal-I) in breast cancerCyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivitySurvivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrenceAbrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumorsBiology and treatment of ductal carcinoma in situ.Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoidImpact of cyclooxygenase-2 over-expression on the prognosis of breast cancer patients.The molecular journey from ductal carcinoma in situ to invasive breast cancer.Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkersDifferential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model
P2860
Q24796824-24C953CD-31E3-469E-9B5B-01B16628B42BQ24796939-F9A79506-89DD-4297-A149-59183EBA59DAQ24806368-FFCEFF72-6882-411C-AC82-337D4CA243DBQ24806468-B87DEBC8-024B-4295-B5B2-59D243068B04Q28187414-4C3920D2-9250-42F2-907C-4A5E6F41B12FQ28194592-A3BA75A5-86E7-49C9-910F-B116F7F29DD4Q28218639-57AC8D0E-1623-465D-846A-3765A0A4370BQ28661521-6014F05E-3B47-438B-9119-9C7A5C9DDBCCQ30367680-B720A956-A6CC-413F-AF6C-F80C6106AEACQ33317621-8221F25C-6080-45EB-BF77-83942E54E25CQ33664316-C94B2B36-3730-4A77-B158-26D8FFC39FD5Q33877411-C3BC95A0-43FF-42A9-96BA-34001E0CB9C7Q33914381-9ACBDD3B-DAC1-433D-93BE-CBE8A540228EQ34032403-23E49F1E-A5F8-46DF-A08D-A5C2A3B90D50Q34072400-AA103A2F-DB4F-4018-A684-65C929827733Q34084150-869E65D5-6410-401E-BAE7-0202BF869D9BQ34194526-4BF02507-22F9-4789-A0D3-4EC320CA7789Q34641787-E13ED8EE-2754-4854-89F3-05BB01AF17F6Q34908885-1CDC6A6F-5EB8-4443-9CE6-8AC49C9E2B01Q34940834-FA661A08-912C-4225-B252-CCCF19EA9838Q34996098-DDEAC0D7-91AA-40E0-B5F7-FAA83CA542A1Q35108403-2770F951-A7BF-4B8F-A201-23012CD46179Q35227086-0937F981-6CEA-4B1E-B466-7341E9148E71Q35572905-56911C89-0859-4547-8C9A-A976D5C0476AQ35614098-896ED31B-D244-4D53-A1E6-8CE0C5642A33Q35722400-B4E2EFEB-8A41-45D5-A3FA-91DF43D88139Q35940085-03A0E62B-65BA-4B7A-9207-EA91AFF6E48DQ35995604-762BF968-F82A-470E-A6C2-515183447DF9Q36135818-2DFF1AB6-C690-4C2B-90B1-6CE60B10A0A4Q36492855-2E0A6BF7-998B-436C-9134-1609D23D2286Q36609908-1A898EC6-1224-4F33-8514-A4A71B337EA3Q36612010-16A9C8EA-3385-4FD6-9861-A112199205CCQ36613564-80BD3F46-64FB-4921-A4D7-275464173F20Q36707456-AE858995-F521-4889-AA44-69DB3E82E5EFQ36731414-E742B3B4-E84B-4B13-8A18-B9136C20BCF8Q37033840-D7BC6715-A329-4D76-860C-E43BB42B0FADQ37088155-170B1EA2-E548-4A5F-917A-3F393D63F52FQ37126345-5F0E7CB8-8528-4CA2-9B4C-2E18979A7D5DQ37326197-DD7AAA35-9262-43B3-97A5-98FED07185CBQ37591395-C3C7B9A8-2C1F-4B1C-82D9-25BD36F1EA5A
P2860
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
@ast
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
@en
type
label
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
@ast
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
@en
prefLabel
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
@ast
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
@en
P2093
P2860
P356
P1476
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601534
P407
P577
2004-01-01T00:00:00Z